Patient characteristics by TERS group (N = 556)
| . | TERS score, n (%) . | P . | ||
|---|---|---|---|---|
| ≤29.5 (n = 199) . | 30-37.5 (n = 181) . | ≥38 (n = 176) . | ||
| Age, y | .06 | |||
| Median | 52 | 52 | 50.5 | |
| Range | 18-75 | 19-77 | 19-73 | |
| Male sex | 116 (58) | 92 (51) | 98 (56) | .34 |
| Race | .30 | |||
| White | 142 (71) | 138 (76) | 128 (73) | |
| Black/African American | 53 (27) | 36 (20) | 39 (22) | |
| Asian | 4 (2) | 7 (4) | 9 (5) | |
| Education level | .85 | |||
| High school | 42 (21) | 42 (23) | 43 (24) | |
| Associate/bachelor’s degree | 87 (44) | 81 (45) | 80 (45) | |
| Master’s/doctorate degree | 21 (11) | 18 (10) | 21 (12) | |
| Unknown | 49 (25) | 40 (22) | 32 (18) | |
| Marital status | .35 | |||
| Single | 33 (17) | 32 (18) | 41 (23) | |
| Married | 143 (72) | 130 (72) | 108 (61) | |
| Divorced/separated | 19 (9) | 14 (7) | 21 (12) | |
| Widowed | 4 (2) | 5 (3) | 6 (4) | |
| Diagnosis | .63 | |||
| AML | 78 (39) | 71 (39) | 72 (41) | |
| ALL | 32 (16) | 27 (15) | 26 (15) | |
| MDS/MPD/CML | 44 (22) | 36 (20) | 25 (14) | |
| NHL/HD/CLL | 33 (17) | 36 (20) | 37 (21) | |
| Other | 12 (6) | 11 (6) | 16 (9) | |
| Donor type | .011 | |||
| MRD | 80 (40) | 78 (43) | 80 (45) | |
| MUD | 22 (11) | 37 (20) | 36 (21) | |
| Haplo | 97 (49) | 66 (37) | 60 (34) | |
| Source | .86 | |||
| BM | 31 (16) | 29 (16) | 30 (17) | |
| PBSCs | 168 (84) | 152 (83) | 146 (82) | |
| Intensity | .52 | |||
| Myeloablative | 104 (52) | 84 (46) | 86 (49) | |
| Nonmyeloablative/RIC | 95 (52) | 97 (54) | 90 (51) | |
| Disease risk | .010 | |||
| Low | 98 (49) | 96 (53) | 83 (47) | |
| Intermediate | 52 (26) | 63 (35) | 65 (37) | |
| High | 46 (23) | 21 (12) | 23 (13) | |
| N/A | 3 (2) | 1 (1) | 5 (3) | |
| HCT-CI | .22 | |||
| 0-2 | 114 (57) | 111 (61) | 92 (52) | |
| ≥3 | 85 (43) | 70 (39) | 84 (48) | |
| KPS | .009 | |||
| 60-80 | 146 (73) | 115 (64) | 103 (59) | |
| 90-100 | 53 (27) | 66 (36) | 73 (41) | |
| Year of transplantation | <.001 | |||
| 2003-2009 | 12 (6) | 52 (29) | 63 (36) | |
| 2010-2014 | 91 (46) | 79 (44) | 72 (41) | |
| 2015-2017 | 96 (48) | 50 (28) | 41 (23) | |
| No. of survivors | 142 | 105 | 105 | |
| Survivor follow-up, mo | <.001 | |||
| Median | 51 | 79 | 83 | |
| Range | 15-181 | 14-184 | 16-182 | |
| . | TERS score, n (%) . | P . | ||
|---|---|---|---|---|
| ≤29.5 (n = 199) . | 30-37.5 (n = 181) . | ≥38 (n = 176) . | ||
| Age, y | .06 | |||
| Median | 52 | 52 | 50.5 | |
| Range | 18-75 | 19-77 | 19-73 | |
| Male sex | 116 (58) | 92 (51) | 98 (56) | .34 |
| Race | .30 | |||
| White | 142 (71) | 138 (76) | 128 (73) | |
| Black/African American | 53 (27) | 36 (20) | 39 (22) | |
| Asian | 4 (2) | 7 (4) | 9 (5) | |
| Education level | .85 | |||
| High school | 42 (21) | 42 (23) | 43 (24) | |
| Associate/bachelor’s degree | 87 (44) | 81 (45) | 80 (45) | |
| Master’s/doctorate degree | 21 (11) | 18 (10) | 21 (12) | |
| Unknown | 49 (25) | 40 (22) | 32 (18) | |
| Marital status | .35 | |||
| Single | 33 (17) | 32 (18) | 41 (23) | |
| Married | 143 (72) | 130 (72) | 108 (61) | |
| Divorced/separated | 19 (9) | 14 (7) | 21 (12) | |
| Widowed | 4 (2) | 5 (3) | 6 (4) | |
| Diagnosis | .63 | |||
| AML | 78 (39) | 71 (39) | 72 (41) | |
| ALL | 32 (16) | 27 (15) | 26 (15) | |
| MDS/MPD/CML | 44 (22) | 36 (20) | 25 (14) | |
| NHL/HD/CLL | 33 (17) | 36 (20) | 37 (21) | |
| Other | 12 (6) | 11 (6) | 16 (9) | |
| Donor type | .011 | |||
| MRD | 80 (40) | 78 (43) | 80 (45) | |
| MUD | 22 (11) | 37 (20) | 36 (21) | |
| Haplo | 97 (49) | 66 (37) | 60 (34) | |
| Source | .86 | |||
| BM | 31 (16) | 29 (16) | 30 (17) | |
| PBSCs | 168 (84) | 152 (83) | 146 (82) | |
| Intensity | .52 | |||
| Myeloablative | 104 (52) | 84 (46) | 86 (49) | |
| Nonmyeloablative/RIC | 95 (52) | 97 (54) | 90 (51) | |
| Disease risk | .010 | |||
| Low | 98 (49) | 96 (53) | 83 (47) | |
| Intermediate | 52 (26) | 63 (35) | 65 (37) | |
| High | 46 (23) | 21 (12) | 23 (13) | |
| N/A | 3 (2) | 1 (1) | 5 (3) | |
| HCT-CI | .22 | |||
| 0-2 | 114 (57) | 111 (61) | 92 (52) | |
| ≥3 | 85 (43) | 70 (39) | 84 (48) | |
| KPS | .009 | |||
| 60-80 | 146 (73) | 115 (64) | 103 (59) | |
| 90-100 | 53 (27) | 66 (36) | 73 (41) | |
| Year of transplantation | <.001 | |||
| 2003-2009 | 12 (6) | 52 (29) | 63 (36) | |
| 2010-2014 | 91 (46) | 79 (44) | 72 (41) | |
| 2015-2017 | 96 (48) | 50 (28) | 41 (23) | |
| No. of survivors | 142 | 105 | 105 | |
| Survivor follow-up, mo | <.001 | |||
| Median | 51 | 79 | 83 | |
| Range | 15-181 | 14-184 | 16-182 | |
CML, chronic myeloid leukemia; HD, Hodgkin disease; KPS, Karnofsky performance score; MDS, myelodysplastic syndrome; MPS, myeloproliferative disease; PBSC, peripheral blood stem cell.